BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They ...
StockStory.org on MSN6h
What To Expect From Myriad Genetics’s (MYGN) Q4 EarningsGenetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
Health and Me on MSN20h
What Is Batten Disease? All About The Fatal Genetic Conditions Causing Waste Build Up In Kids BrainBatten disease is a rare genetic disorder affecting 3 in 100,000 babies in the U.S., causing neurodegeneration, seizures, ...
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo/File Photo The U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback